Application of 3D Bioprinting Technologies to the Management and Treatment of Diabetic Foot Ulcers

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2020 Oct 24

PMID 33096771

Citations 13

Authors

Chew Teng Tan

Kun Liang

Zong Heng Ngo

Christabel Thembela Dube

Chin Yan Lim

Affiliations

Soon will be listed here.

Abstract

Diabetes mellitus (DM) is a chronic metabolic disease with increasing prevalence worldwide. Diabetic foot ulcers (DFUs) are a serious complication of DM. It is estimated that 15-25% of DM patients develop DFU at least once in their lifetime. The lack of effective wound dressings and targeted therapy for DFUs often results in prolonged hospitalization and amputations. As the incidence of DM is projected to rise, the demand for specialized DFU wound management will continue to increase. Hence, it is of great interest to improve and develop effective DFU-specific wound dressings and therapies. In the last decade, 3D bioprinting technology has made a great contribution to the healthcare sector, with the development of personalized prosthetics, implants, and bioengineered tissues. In this review, we discuss the challenges faced in DFU wound management and how 3D bioprinting technology can be applied to advance current treatment methods, such as biomanufacturing of composite 3D human skin substitutes for skin grafting and the development of DFU-appropriate wound dressings. Future co-development of 3D bioprinting technologies with novel treatment approaches to mitigate DFU-specific pathophysiological challenges will be key to limiting the healthcare burden associated with the increasing prevalence of DM.

Citing Articles

New Perspectives of Hydrogels in Chronic Wound Management.

Alberts A, Bratu A, Niculescu A, Grumezescu A Molecules. 2025; 30(3).

PMID: 39942790 PMC: 11820815. DOI: 10.3390/molecules30030686.

Application of 3D printing in the treatment of diabetic foot ulcers: current status and new insights.

Li X, Ai X, Wang B, Luo M, Miyamoto A, Kuchay M Front Bioeng Biotechnol. 2024; 12:1475885.

PMID: 39605746 PMC: 11598536. DOI: 10.3389/fbioe.2024.1475885.

Tissue Bioprinting: Promise and Challenges.

Liang K Bioengineering (Basel). 2023; 10(12).

PMID: 38135991 PMC: 10740401. DOI: 10.3390/bioengineering10121400.

A Berberine-Loaded Polysaccharide Hydrogel as a New Medical Dressing for Diabetic Wound Healing.

Hu Z, Zhao K, Chen X, Zhou M, Chen Y, Ye X Int J Mol Sci. 2023; 24(22).

PMID: 38003478 PMC: 10671592. DOI: 10.3390/ijms242216286.

Performance of hybrid gelatin-PVA bioinks integrated with genipin through extrusion-based 3D bioprinting: An evaluation using human dermal fibroblasts.

Masri S, Maarof M, Aziz I, Idrus R, Fauzi M Int J Bioprint. 2023; 9(3):677.

PMID: 37274005 PMC: 10236347. DOI: 10.18063/ijb.677.

References

Kumar M, Roe K, Nerurkar P, Orillo B, Thompson K, Verma S . Reduced immune cell infiltration and increased pro-inflammatory mediators in the brain of Type 2 diabetic mouse model infected with West Nile virus. J Neuroinflammation. 2014; 11:80. PMC: 4001407. DOI: 10.1186/1742-2094-11-80. View

Lopes L, Setia O, Aurshina A, Liu S, Hu H, Isaji T . Stem cell therapy for diabetic foot ulcers: a review of preclinical and clinical research. Stem Cell Res Ther. 2018; 9(1):188. PMC: 6042254. DOI: 10.1186/s13287-018-0938-6. View

Amin A, Abd Elmageed Z, Nair D, Partyka M, Kadowitz P, Belmadani S . Modified multipotent stromal cells with epidermal growth factor restore vasculogenesis and blood flow in ischemic hind-limb of type II diabetic mice. Lab Invest. 2010; 90(7):985-96. PMC: 3154725. DOI: 10.1038/labinvest.2010.86. View

Veves A, Sheehan P, Pham H . A randomized, controlled trial of Promogran (a collagen/oxidized regenerated cellulose dressing) vs standard treatment in the management of diabetic foot ulcers. Arch Surg. 2002; 137(7):822-7. DOI: 10.1001/archsurg.137.7.822. View

Park J, Shim J, Choi S, Jang J, Kim M, Lee S . 3D printing technology to control BMP-2 and VEGF delivery spatially and temporally to promote large-volume bone regeneration. J Mater Chem B. 2020; 3(27):5415-5425. DOI: 10.1039/c5tb00637f. View

Guariguata L, Whiting D, Hambleton I, Beagley J, Linnenkamp U, Shaw J . Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014; 103(2):137-49. DOI: 10.1016/j.diabres.2013.11.002. View

Ortega-Gomez A, Perretti M, Soehnlein O . Resolution of inflammation: an integrated view. EMBO Mol Med. 2013; 5(5):661-74. PMC: 3662311. DOI: 10.1002/emmm.201202382. View

Wu Y, Wang J, Scott P, Tredget E . Bone marrow-derived stem cells in wound healing: a review. Wound Repair Regen. 2008; 15 Suppl 1:S18-26. DOI: 10.1111/j.1524-475X.2007.00221.x. View

Fadok V, Bratton D, Konowal A, Freed P, Westcott J, Henson P . Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest. 1998; 101(4):890-8. PMC: 508637. DOI: 10.1172/JCI1112. View

10.

Hinz B, Celetta G, Tomasek J, Gabbiani G, Chaponnier C . Alpha-smooth muscle actin expression upregulates fibroblast contractile activity. Mol Biol Cell. 2001; 12(9):2730-41. PMC: 59708. DOI: 10.1091/mbc.12.9.2730. View

11.

Li L, Zhang J, Zhang Q, Zhang D, Xiang F, Jia J . High Glucose Suppresses Keratinocyte Migration Through the Inhibition of p38 MAPK/Autophagy Pathway. Front Physiol. 2019; 10:24. PMC: 6360165. DOI: 10.3389/fphys.2019.00024. View

12.

Andreea S, Marieta C, Anca D . AGEs and glucose levels modulate type I and III procollagen mRNA synthesis in dermal fibroblasts cells culture. Exp Diabetes Res. 2008; 2008:473603. PMC: 2288745. DOI: 10.1155/2008/473603. View

13.

Baltazar T, Merola J, Catarino C, Xie C, Kirkiles-Smith N, Lee V . Three Dimensional Bioprinting of a Vascularized and Perfusable Skin Graft Using Human Keratinocytes, Fibroblasts, Pericytes, and Endothelial Cells. Tissue Eng Part A. 2019; 26(5-6):227-238. PMC: 7476394. DOI: 10.1089/ten.TEA.2019.0201. View

14.

Dash N, Dash S, Routray P, Mohapatra S, Mohapatra P . Targeting nonhealing ulcers of lower extremity in human through autologous bone marrow-derived mesenchymal stem cells. Rejuvenation Res. 2009; 12(5):359-66. DOI: 10.1089/rej.2009.0872. View

15.

Streit M, Braathen L . Apligraf--a living human skin equivalent for the treatment of chronic wounds. Int J Artif Organs. 2001; 23(12):831-3. View

16.

Spravchikov N, Sizyakov G, Gartsbein M, Accili D, Tennenbaum T, WERTHEIMER E . Glucose effects on skin keratinocytes: implications for diabetes skin complications. Diabetes. 2001; 50(7):1627-35. DOI: 10.2337/diabetes.50.7.1627. View

17.

Jiang Y, Ran X, Jia L, Yang C, Wang P, Ma J . Epidemiology of type 2 diabetic foot problems and predictive factors for amputation in China. Int J Low Extrem Wounds. 2015; 14(1):19-27. DOI: 10.1177/1534734614564867. View

18.

Lipsky B, Holroyd K, Zasloff M . Topical versus systemic antimicrobial therapy for treating mildly infected diabetic foot ulcers: a randomized, controlled, double-blinded, multicenter trial of pexiganan cream. Clin Infect Dis. 2008; 47(12):1537-45. DOI: 10.1086/593185. View

19.

Kang H, Lee S, Ko I, Kengla C, Yoo J, Atala A . A 3D bioprinting system to produce human-scale tissue constructs with structural integrity. Nat Biotechnol. 2016; 34(3):312-9. DOI: 10.1038/nbt.3413. View

20.

Hiller T, Berg J, Elomaa L, Rohrs V, Ullah I, Schaar K . Generation of a 3D Liver Model Comprising Human Extracellular Matrix in an Alginate/Gelatin-Based Bioink by Extrusion Bioprinting for Infection and Transduction Studies. Int J Mol Sci. 2018; 19(10). PMC: 6213460. DOI: 10.3390/ijms19103129. View